These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28722246)

  • 21. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
    Romero TR; Resende LC; Guzzo LS; Duarte ID
    Anesth Analg; 2013 Feb; 116(2):463-72. PubMed ID: 23302980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.
    Rosati O; Messina F; Pelosi A; Curini M; Petrucci V; Gertsch J; Chicca A
    Eur J Med Chem; 2014 Oct; 85():77-86. PubMed ID: 25072877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of cannabinoid CB1 receptors suppresses the ROS-induced hypersensitivity of rat vagal lung C-fiber afferents.
    Yeh CM; Ruan T; Lin YJ; Hsu TH
    Pulm Pharmacol Ther; 2016 Oct; 40():22-9. PubMed ID: 27328978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Δ
    Darmani NA; Belkacemi L; Zhong W
    Eur J Pharmacol; 2019 Dec; 865():172806. PubMed ID: 31738934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. β
    Cairns BE; He N
    J Oral Rehabil; 2024 Oct; 51(10):1997-2007. PubMed ID: 38894554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of CP55,940 on mechanosensory spinal neurons following chronic inflammation.
    Choong KC; Su X; Urban MO
    Neurosci Lett; 2007 Mar; 414(2):105-9. PubMed ID: 17194542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Δ
    Shang VC; Kendall DA; Roberts RE
    Biochem Pharmacol; 2016 Nov; 120():63-71. PubMed ID: 27641813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Similarities and differences upon binding of naturally occurring Δ
    Raïch I; Rivas-Santisteban R; Lillo A; Lillo J; Reyes-Resina I; Nadal X; Ferreiro-Vera C; de Medina VS; Majellaro M; Sotelo E; Navarro G; Franco R
    Pharmacol Res; 2021 Dec; 174():105970. PubMed ID: 34758399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
    Haller VL; Cichewicz DL; Welch SP
    Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
    Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
    Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additive antiemetic efficacy of low-doses of the cannabinoid CB(1/2) receptor agonist Δ(9)-THC with ultralow-doses of the vanilloid TRPV1 receptor agonist resiniferatoxin in the least shrew (Cryptotis parva).
    Darmani NA; Chebolu S; Zhong W; Trinh C; McClanahan B; Brar RS
    Eur J Pharmacol; 2014 Jan; 722():147-55. PubMed ID: 24157976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.
    Pertwee RG
    Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3353-63. PubMed ID: 23108552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM; Wakley AA; Tsutsui KT; Laggart JD
    J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors.
    Romero TR; Pacheco Dda F; Duarte ID
    Life Sci; 2013 May; 92(14-16):815-20. PubMed ID: 23123446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
    Rao GK; Kaminski NE
    J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The synthetic CB
    Coronado-Álvarez A; Romero-Cordero K; Macías-Triana L; Tatum-Kuri A; Vera-Barrón A; Budde H; Machado S; Yamamoto T; Imperatori C; Murillo-Rodríguez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Aug; 110():110301. PubMed ID: 33741446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors.
    Quartilho A; Mata HP; Ibrahim MM; Vanderah TW; Porreca F; Makriyannis A; Malan TP
    Anesthesiology; 2003 Oct; 99(4):955-60. PubMed ID: 14508331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of cannabinoid 1 and, 2 receptors and the effects of cannabinoid 1 and, 2 receptor agonists on detrusor overactivity associated with bladder outlet obstruction in rats.
    Kim SD; Cho KJ; Kim JC
    BMC Urol; 2017 Dec; 17(1):121. PubMed ID: 29284441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.
    Springs AE; Karmaus PW; Crawford RB; Kaplan BL; Kaminski NE
    J Leukoc Biol; 2008 Dec; 84(6):1574-84. PubMed ID: 18791168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Trigeminal purinergic P2X4 receptor involved in experimental occlusal interference-induced hyperalgesia in rat masseter muscle].
    Xu X; Cao Y; Ding T; Fu K; Xie Q
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2016 Mar; 51(3):176-81. PubMed ID: 26980657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.